Daratumumab and corticosteroid treatment

ApprovedSmall molecule

IInstitute of Hematology & Blood Diseases Hospital, China

Daratumumab and corticosteroid treatment is one of 8 small molecule programs targeting Acquired Hemophilia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acquired HemophiliaActive, not recruiting

Acquired HemophiliaApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Acquired Hemophilia

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

1 2

Rituxan

Pfizer

Phase 3

1 3

Hemlibra

Roche

Phase 2

2 4

Rituxan

Roche

Phase 2

1 5

Velcade

SShilpa Grover, MD, MPH

Phase 2

1 6

Daratumumab and corticosteroid treatment

IInstitute of Hematology & Blood Diseases Hospital, China

Approved

1 7

OBI-1

BBaxalta now part of Shire

Phase 3

2 8

OBIZUR

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Acquired Hemophilia

NCT05849740

Clinical

Trials by Indication[1]

Acquired Hemophilia1 trial

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05849740·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Daratumumab and corticosteroid treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daratumumab and corticosteroid treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daratumumab and corticosteroid treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

Daratumumab and corticosteroid treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acquired Hemophilia1 trial

References

Drug Info

Quick Facts

Related News